



Ursula Amstutz

Kontakt

Ursula Amstutz

Publikationen (11)

Born A, Bocchi F, Kuhn C, Amstutz U, Baumgartner M, Sidler D. Tacrolimus monitoring in hair samples of kidney transplant recipients. *Front Med (Lausanne)* 2023; 10:1307505.

Gallon J, Rodriguez-Calero A, Benjak A, Akhoundova D, Maletti S, Amstutz U, Hewer E, Genitsch V, Fleischmann A, Rushing E, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya A, Bubendorf L, Moch H, Thalmann G, Feng F, Gillessen S, Chiang C, Rubin M, Piscuoglio S. DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations. *Cancer Res* 2023; 83:1203–1213.

Kueng N, Arcioni S, Sandberg F, Kuhn C, Banz V, Largiadèr C, Sidler D, Amstutz U. Comparison of methods for donor-derived cell-free DNA quantification in plasma and urine from solid organ transplant recipients. *Front Genet* 2023; 14:1089830.

Begré U, Jörgler M, Aebi S, Amstutz U, Largiadèr C. Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland. *Front Pharmacol* 2022; 13:885259.

Rodriguez-Calero A, Gallon J, Akhoundova D, Maletti S, Ferguson A, Cyrta J, Amstutz U, Garofoli A, Paradiso V, Tomlins S, Hewer E, Genitsch V, Fleischmann A, Vassella E, Rushing E, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya A, Bubendorf L, Moch H, Thalmann G, Ng C, Gillessen S, Piscuoglio S, Rubin M. Alterations in homologous recombination repair genes in prostate cancer brain metastases. *Nat Commun* 2022; 13:2400.

Hamzic S, Aebi S, Jörgler M, Montemurro M, Ansari M, Amstutz U, Largiadèr C. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy. *Swiss Med Wkly* 2020; 150:w20375.

Schaerer D, Froehlich T, Hamzic S, Offer S, Diasio R, Jörgler M, Amstutz U, Largiadèr C. A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies. *J Pers Med* 2020; 10

Hamzic S, Amstutz U, López-Fernández L, García-González X, Schellens J, Meulendijks D, Thomlinson I, Palles C, Aebi S, Jörgler M, Froehlich T, Kummer D, Largiadèr C. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. *Pharmacol Res* 2019; 152:104594.

Kummer D, Froehlich T, Joerger M, Aebi S, Sistonen J, Amstutz U, Largiadèr C. Dihydropyrimidinase and β -ureidopropionase gene variation and severe fluoropyrimidine-related toxicity. *Pharmacogenomics* 2015; 16:1367–77.

Amstutz U, Offer S, Sistonen J, Joerger M, Diasio R, Largiadèr C. Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy. *Clin Cancer Res* 2015; 21:2038–44.

Froehlich T, Amstutz U, Aebi S, Jörgler M, Largiadèr C. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. *Int J Cancer* 2014; 136:730–9.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch